Korro Bio doses first cohort in Phase 1/2 ANCHOR trial
Korro Bio has dosed the first cohort in its Phase 1/2 ANCHOR trial of KRRO-121, administering a 2 mg/kg single dose to healthy volunteers.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Korro Bio (KRRO.O) dosed first healthy volunteers in Phase 1/2 ANCHOR KRRO-121
Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia; single 2 mg/kg dose, with interim readout expected in 2H 2027 and patient dosing expected in H1 2027.